chrisvoncsefalvay/vaers-outcomes huggingface dataset:
red area where you received your shot; raised area where you received you shot; This case was reported by a consumer via interactive digital media and described the occurrence of injection site erythema in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced injection site erythema and injection site swelling. On an unknown date, the outcome of the injection site erythema and injection site swelling were unknown.   It was unknown if the reporter considered the injection site erythema and injection site swelling to be related to Shingles vaccine.  Additional details provided were as follows: The case was self-reported by the patient. The age at vaccination was not reported. The patient received a dose of Shingles vaccine and had a very large raised red area where he/she received the shot. Follow-up would not be possible as no contact details available.
When she recieved the flu shot she felt okay. She had a little twinge but nothing else. Over the next few weeks she developed pain in her arm and had difficulty raising the arm above the shoulder. She has trouble sleeping as the arm is painful especially when rolling over on it. It is like a shock pain that "takes her breath away". The pain is improving and arm movement as well but not completely better.
significant fatigue; significant myalagias; This case was reported by a physician via call center representative and described the occurrence of myalgia in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced myalgia and fatigue. On an unknown date, the outcome of the myalgia was recovered/resolved and the outcome of the fatigue was unknown.   It was unknown if the reporter considered the myalgia and fatigue to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The patient received 1st dose of Shingrix and experienced significant myalgia for 4 days and significant fatigue. The reporter was asking that how important was it to patient to receive 2nd dose of Shingrix.
Is swollen for couple days Real big swollen and then when a week  left a lipoma on my Arm
This is a spontaneous report from a contactable other healthcare professional calling on behalf of a physician. An 8 month-old male patient of an unspecified ethnicity received PREVNAR 13 at single dose via an unspecified route of administration on an unspecified day in Dec2017 (3 or 4 weeks before this report) for immunisation. The patient medical history and concomitant medications were not reported. The patient experienced wheezing on an unspecified date in Dec2017 (3 or 4 weeks before this report). In response to the event Albuterol nebulizer treatment was given. Outcome was unknown.
This spontaneous report was received from a medical assistant and refers to an unspecified multiple patients of unknown age and gender. The patients' pertinent medical history and drug reactions or allergies were not reported. On an unknown date, multiple doses of improperly stored PROQUAD lot number reported as M041508, expiration date: 09-APR-2018 (dose and route of administration were not reported) were administered to unspecified patients. It was verified that sterile diluent used to reconstitute vaccines was properly stored. No adverse effects were reported. Administered dose of vaccine experienced the temperature excursion of -14 to -10 degrees of Celsius for 105 minutes. It was reported that the vaccines experienced previous temperature excursion (not specified). Data logger was involved. This is one of two reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1705USA005747:
Case was vaccinated for Covid in February 2021, then hospitalized with Covid January 2022. Hospitalized  COVID-19 Assessment & Plan Was due to be discharged 1/5 but tested positive on pre-discharge Covid screen. She received 2 doses of Moderna vaccine in 1/2021 and 2/2021. Initially asymptomatic, but developed fever and increased O2 requirement on 1/7. CXR c/w viral pneumonia. She completed courses of remdesivir and dexamethasone and is back on her usual 2L O2
SECONDARY EFFECTS; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced secondary effects. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of secondary effects was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure as the case was assessed as non-serious.
On July 13, 2017, it was noticed that the temps were out of range on July 9 at 60.6 for 12.10 hours.
chills.....fever 101.5......high bp 174 over 100  pulse 100   heart racing
Patient was asked to remain in pharmacy observation after receiving vaccine; he left to go up to front of store at which time he blacked out and felt faint; he states that this happens to him whenever he receives a vaccination; we were notified by the store manager as to his location; he was drinking Gatorade; it is now 1:20 pm and he is under observation currently; does not report anymore symptoms and feels better
pt recvd vax 10NOV93 @ 1130AM; no problems were noted; pt had rash & whelps on face & chest area; no SOB or resp problems; no itching; pt to ER or MD ASAP for medical eval;
Patient experienced burning and pain at injection site. Also describes burning pain in muscles and joints throughout his body. Onset in the evening after vaccination that afternoon and lasted through the evening. Treated with tylenol and symptoms began to resolve.
sinus infection; This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (sinus infection) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Mar-2021, the patient experienced SINUSITIS (sinus infection). The patient was treated with AMOXICILLIN at an unspecified dose and frequency. At the time of the report, SINUSITIS (sinus infection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.
Right arm swelling and redness along with itchiness. Fever on day of vaccines. Other symptoms started on 8/24/16 at 07:15. Treatment: diphenhydramine 12.5mg/5ml and hydrocortisone-aloe 1% prescribed on 8/25/16.
Patient was accidently given an empty syringe.  We realized very shortly & administed the covid vaccine.  There was no adverse event.
Patient has soreness and tenderness at the site of injection, which started on 5/2/18. The injection site is also red and warm to the touch, which started today 5/3/18.
The day after receiving Hep. A and Hep B pt developed a rash on his hands, arms and feet. He also had trouble breathing. His mother took him to his primary physician and he advised pt to never take Hep A or Hep B again.
This spontaneous case reported by a consumer, describes the occurrence of pyrexia (fever) in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On an unknown date, patient received a dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced pyrexia (fever). At the time of the report, pyrexia (fever) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. No concomitant medication or treatment information reported.
Clammy; Temperature of 100 degrees F; Arm was terribly sore; Arm was red; This spontaneous case was reported by a consumer and describes the occurrence of COLD SWEAT (Clammy), VACCINATION SITE PAIN (Arm was terribly sore), VACCINATION SITE ERYTHEMA (Arm was red) and PYREXIA (Temperature of 100 degrees F) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included OLMESARTAN, ZINC, VITAMIN D NOS, GLUCOSAMINE and ASCORBIC ACID (VITAMIN C FLAVOUR) for an unknown indication.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced VACCINATION SITE PAIN (Arm was terribly sore) and VACCINATION SITE ERYTHEMA (Arm was red). On 14-Jan-2021, the patient experienced PYREXIA (Temperature of 100 degrees F). On 15-Jan-2021, the patient experienced COLD SWEAT (Clammy). At the time of the report, COLD SWEAT (Clammy), VACCINATION SITE PAIN (Arm was terribly sore), VACCINATION SITE ERYTHEMA (Arm was red) and PYREXIA (Temperature of 100 degrees F) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment reported was Tylenol for fever and some muscle cream for sore arm which both helped.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site itching in a 61-year-old female patient who received SHINGRIX (batch number 2Y9R4, expiry date 28th June 2021) for prophylaxis. On 13th March 2019, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. In March 2019, less than a week after receiving SHINGRIX, the patient experienced injection site itching, injection site swelling, injection site blisters, injection site bruising and blister rupture. On an unknown date, the outcome of the injection site itching, injection site swelling, injection site blisters, injection site bruising and blister rupture were unknown. It was unknown if the reporter considered the injection site itching, injection site swelling, injection site blisters, injection site bruising and blister rupture to be related to SHINGRIX. Additional details were provided as follows: The patient received 1st dose of the SHINGRIX vaccine in left deltoid. Within 3 to 4 days, the consumer began to experience itching and swelling at the injection site. This got progressively worse and a bruise developed that had blisters on it. The blisters opened up and the consumer had a depression that was approximately 2 inches long and half inch wide. He said the area looks like it had been scooped off and raw. The health care professional did not diagnose blisters as being a Herpes Zoster rash. The registered pharmacist did mention the word rash at injection site during conversation. The consumer was in the pharmacy and provide permission for her physician to be contacted.
pt recv vax 12SEP95 & devel a fever between 103-104 8-9 days p/vax;2 other children in addtl to this child twin recv same lot# &exp t103-104;dec appetite;
Narrative: 80 yo male pt with small cell lung cancer in home hospice care died on 6/15/2021 from lung cancer. Pt had received covid vaccinations on 1/14/2021 & 2/11/2021. Vaccinations unrelated to pt's death. Reporting since vaccine is EUA status.
injection site arm was sore for several days after both shots/could not sleep on injection site arm; headaches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (injection site arm was sore for several days after both shots/could not sleep on injection site arm) and HEADACHE (headaches) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048A21A and 01A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced VACCINATION SITE PAIN (injection site arm was sore for several days after both shots/could not sleep on injection site arm) and HEADACHE (headaches). At the time of the report, VACCINATION SITE PAIN (injection site arm was sore for several days after both shots/could not sleep on injection site arm) had resolved and HEADACHE (headaches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment details were provided.   This case was linked to MOD-2021-362790 (Patient Link).
Systemic: Confusion-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Nausea-Mild, Systemic: Seizure-Medium, Additional Details: Patient recieved first dose of Pfizer vaccine administered by Staff. Patient appeared confused and lethargic appearing to pass out. Staff administered epinephrine. Patient then started to seize ~2 mins. Patient was then reponsive. Emergency services came and took patient to hospital.
Syndrome of facial ticks and altered taste began 11/17 and became recognizable as Bell's Palsy by 11/19.
covid test result=Positive; covid test result=Positive; This is a spontaneous report from a contactable other healthcare professional (other HCP reporting for himself).  A 39-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE Solution for injection, batch/lot no. and expiry date unknown), via an unspecified route of administration on 16Dec2020 12:45 (1st dose) at a single dose on his left arm for COVID-19 immunization.  The patient medical history was not reported.  Concomitant medication included hydrochlorothiazide, losartan potassium (HYZAAR), omeprazole, and ibuprofen; all on unspecified dates for unspecified indications. The patient previously took amoxicillin and experienced allergies. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine, he was also not diagnosed with COVID-19 prior to vaccination. However, since the medication, the patient has been tested positive for COVID-19. Patient had his nasal swab on 22Dec2020, and it turned out positive (COVID test result=positive).  Outcome of the event drug ineffective and COVID-19 virus test positive was unknown. Facility where the most recent COVID-19 vaccine was administered at the hospital.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the information currently available, a lack of efficacy with the suspected vaccine BNT162B2 cannot be completely excluded. However, it is unlikely that the patient would have fully developed immunity due to the very short time lag between the first vaccine dose and the event onset.
Within minutes of receiving first COVID vaccine, patient  experienced a feeling of warmth, lightheadedness  and elevated blood pressure of 210/110.  BP down to 170/100 at the time of leaving appointment (20 minutes after shot). The next day she felt nausea, Ha, body aches and burning sensation down the arm of the injection.
Weakness, numbness (motor & sensory) all 4 extremities. Elevated CPK & muscle pain. Guillain Barre --> IVIG.
Vaccine for ages 5-11 was not diluted as required. No side effects or adverse event reported by caregiver.
Reddish rash on the top of my chest . Warm to the touch.  Reddish bumps
Urticaria over (L) upper arm. Swelling, muscle soreness. Treatment - Ibuprofen, Benadryl PRN.
Several hours after vaccination patient had unsustained episodes of defibrillation several times that evening and into the following day that resolved after that. It caused his defibrillator to pace him a couple times. No further symptoms. Has had defibrillator since 2004.
Two days ago got 4 yr immunes. Woke up the next day covered in hives. Treated with BENADRYL. No oropharynx symptoms. No shortness of breath or increased work of breathing. Also complains of abdominal pain. No vomiting. No new exposure to soaps, detergents, lotions, foods, clothes. No fever. No cough, runny nose, nasal congestion. No sore throat. Diagnosed - immunization reaction/primary allergic reaction. Advised - ZYRTEC Q day and BENADRYL Q 6 hrs prn. Symptoms may last for one week or longer. Call if last greater than 3 wks.
pt recvd vax & 24-48hrs p/vax exp paresthesia in legs, h/a & pain in neck & shoulder;
I had some pretty bad back problems and the reason I went to the doctor was because it was lasting for more than 3 days. Hip flexors were really tight and causing my back pain. I have had something similar happen before but it's always resolved itself within a week. And now I'm three weeks out and still having this back pain and hip flexor tightness. For the first two weeks - the PT said I should be laying down or standing and only sitting for 5 minutes to help those hip flexors. I'm limited now on activities that I can do. I am not suppose to lift over 20 pounds or bend over. I can't sit cross legged on the floor. PT gave me exercises to do to help.
Pt developed swelling and tenderness of quadriceps within 24 hours.  On 8.9.04 he developed a rash, for which he was seen 8.10.04.  The injection site was slightly crusted, with a few pink macules surrounding it.  Initially treated for impetigo, but on 8.11.04, the macules had become typical target lesions of urticaria.
Significant induration and erythema at shoulder (site of injection) and down proximal arm in a gravitational pattern distally. I saw a similar reaction 1 week ago, can't remember pt's name.
Approximately 30 minutes after injection of TDaP and MCV4 pt's forearms and face started turning red. Took BENADRYL 50mg at 1330.
Describes reaction of welt (redness and warmth) at previous vaccine site (in 2000). Then received half doses at HCP this year: Vaccine administered 10/28/04 at left arm. Denies any mark/irritation of left arm. C/o itching and redness, chest and neck about 4 hours later and blotchy red areas (itchy) on both legs 10/29 less red today 11/01/04.
pt recvd vax & 3 days post vax exp gross hematuria;pt was evaluated by urologist on 30JAN95 & placed on Bactrim;
Patient complained of restless, heart racing, anxious, felt like her blood pressure was up (did not take BP meds this morning) after immunization.  Patient checked out by EMS.   Patient advised to call 911 or go to the nearest emergency room for any additional issues as needed.  Also advised to sign up for v-safe.  Patient left site after being seen by EMS.
After 1st shot, given in May, started her period two days after the shot, and again 3 weeks later, and again June 22nd. Redness, swelling, and itchy at injection site after both doses. Same issues with period after 2nd shot. Also suffered migraine headache 6/23/2021. Still has headaches and injection site redness.
Cellulitis: 2in x 2in warm, red indurated with tiny papule vesicles around presumed injection site. Treated with cephalexin 250mg/5ml: take 5.5 ml TID for 7 days.
paresthesia from elbow to hand in rt arm upon awaking today;bitten by raccoon on rt index finger on 8SEP94;1st dose of vax given in rt deltoid;2nd dose given lt deltoid;11OCT94 f/u series completed w/o further events
Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Medium, Systemic: Chest Tightness / Heaviness / Pain-Medium, Systemic: Chills-Medium, Systemic: Confusion-Medium, Systemic: Dizziness / Lightheadness-Severe, Systemic: Exhaustion / Lethargy-Severe, Systemic: Flushed / Sweating-Severe, Systemic: Headache-Severe, Systemic: Hypertension-Medium, Systemic: Shakiness-Severe, Systemic: Tachycardia-Medium, Systemic: Visual Changes/Disturbances-Severe, Systemic: Weakness-Severe, Additional Details: Patient appeared weak, pale, sweaty, shaky about 5 minutes after the first dose was given to her. She complained of visual disturbances and progressive shortness of breath. Stated her throat felt a little tight but was not experiencing and swelling of of any parts of her face. She then complained of an intense headache that was getting worse. Patient was admitted to the hospital to make sure she was ok.
1st pain at injection site, then approximately 21 hours later fever to 105 degrees F, delirium, induration at injection site to 12 cm with blanching extending up to iliac crest & down to knee; fever persisted for 3 days & pain/swelling of injection site lasted 1 week.
"Covid Arm". Developed a hot, red, itchy welt at the injection site 10 days post-injection. Today is day 13 and it is gradually going away. I've used 2% Hydrocortisone cream on it 3x.